This study is to evaluate the safety, pharmacokinetics characteristics, and antiviral activities of multiple doses of VIR-2218 in adults with chronic HBV infection in mainland China.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of Treatment-emergent Adverse Events (TEAEs)
Timeframe: up to 48 weeks
Clinical Assessments Including But Not Limited to Laboratory Test Results
Timeframe: up to 48 weeks